Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.37 USD
-0.03 (-2.14%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $1.39 +0.02 (1.46%) 6:20 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
AKBA 1.37 -0.03(-2.14%)
Will AKBA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AKBA
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Here's Why You Should Consider Buying Akebia (AKBA) Stock
AKBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
5 Small Drug Stocks to Buy as Innovation Reaches Peak
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?
Other News for AKBA
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo? (vadadustat) for Patients on Dialysis
Akebia and U.S. Renal Care initiate trial of Vafseo for patients on dialysis
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Present at Upcoming Investor Conferences
Talis: Q2 Earnings Snapshot